Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties

Talwar, G.P.; Gupta, Jagdish C.; Mustafa, Abu Salim; Kar, Hemanta Kumar; Katoch, Kiran; Parida, Shreemanta K.; Reddi, Prabhakara P.; Ahmed, Niyaz; Saini, Vikram; Gupta, Somesh

doi:10.2147/btt.s128308

Cited by 20 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MIP has been found to be highly efficacious in treatment of Category II "Difficult to treat" tuberculosis patients (Table 2). Figure 5 shows that the relapse rate of patients treated with MIP is much lower than those receiving drugs alone [13]. Figure 9) [19].…”

Section: Additional Properties Of the Mip Vaccinementioning

confidence: 95%

“…What is further amazing is their conversion to lepromin positivity status (Figure 3), enhancing their ability to resist becoming again a patient of leprosy [13].…”

Section: Figure 2: Some Representative Cases Of Ll/bl Multibacillary mentioning

confidence: 99%

“…In fact prevention of tuberculosis in guinea pigs after inoculation of Tuberculosis H 37 R v is the biological test carried out on each batch of MIP grown by the company manufacturing the vaccine. Furthermore in contrast to BCG, MIP has no genetic restrictions and prevents tuberculosis in all strains of mice (Figure 4) [13]. MIP has been found to be highly efficacious in treatment of Category II "Difficult to treat" tuberculosis patients (Table 2).…”

Section: Additional Properties Of the Mip Vaccinementioning

confidence: 99%

See 2 more Smart Citations

A Unique Vaccine with Multiple Applications

2019

JCEI

View full text Add to dashboard Cite

The immune system consists of molecules and cells (and their products) to keep the Body free of afflictions. Clinical problems arise as and when there is failure or inadequate immunological response. How can the immune system be fortified against an undesirable infection? This is done by making of a vaccine against that infection. This article describes the development of a Vaccine against Leprosy. Most of us (>90%) are immune to this disease. The few, who become victims to leprosy, manifest pitiable symptoms. Interestingly this vaccine has found multiple applications. It is a potent invigorator of immune responses.

show abstract

Section: Additional Properties Of the Mip Vaccinementioning

confidence: 95%

“…What is further amazing is their conversion to lepromin positivity status (Figure 3), enhancing their ability to resist becoming again a patient of leprosy [13].…”

Section: Figure 2: Some Representative Cases Of Ll/bl Multibacillary mentioning

confidence: 99%

Section: Additional Properties Of the Mip Vaccinementioning

confidence: 99%

See 1 more Smart Citation

A Unique Vaccine with Multiple Applications

2019

JCEI

View full text Add to dashboard Cite

show abstract

“…Until recently, immunotherapy options for leprosy were limited to the live vaccine BCG [ 59 – 61 ]. Renewed efforts to develop partially effective vaccines, such as different BCG strains, into improved leprosy vaccines [ 62 , 63 ] have resulted in Mycobacterium indicus pranii (MIP), a whole cell vaccine of heat-killed mycobacteria [ 64 ]. The ideal vaccine against leprosy would need to induce strong, long-lasting T cell responses directed against M. leprae antigens, thereby limiting infection, preventing disease, and reducing bacterial transmission to others [ 65 , 66 ].…”

Section: Panel: the Research Priorities To Achieve Zero Leprosymentioning

confidence: 99%

A comprehensive research agenda for zero leprosy

et al. 2020

View full text Add to dashboard Cite

Background Leprosy control achieved dramatic success in the 1980s–1990s with the implementation of short course multidrug therapy, which reduced the global prevalence of leprosy to less than 1 in 10 000 population. However, a period of relative stagnation in leprosy control followed this achievement, and only limited further declines in the global number of new cases reported have been achieved over the past decade. Main text In 2016, major stakeholders called for the development of an innovative and comprehensive leprosy strategy aimed at reducing the incidence of leprosy, lowering the burden of disability and discrimination, and interrupting transmission. This led to the establishment of the Global Partnership for Zero Leprosy (GPZL) in 2018, with partners aligned around a shared Action Framework committed to achieving the WHO targets by 2030 through national leprosy program capacity-building, resource mobilisation and an enabling research agenda. GPZL convened over 140 experts from more than 20 countries to develop a research agenda to achieve zero leprosy. The result is a detailed research agenda focusing on diagnostics, mapping, digital technology and innovation, disability, epidemiological modelling and investment case, implementation research, stigma, post exposure prophylaxis and transmission, and vaccines. This research agenda is aligned with the research priorities identified by other stakeholders. Conclusions Developing and achieving consensus on the research agenda for zero leprosy is a significant step forward for the leprosy community. In a next step, research programmes must be developed, with individual components of the research agenda requiring distinct expertise, varying in resource needs, and operating over different timescales. Moving toward zero leprosy now requires partner alignment and new investments at all stages of the research process, from discovery to implementation.

show abstract

“…The first of these is Mycobacterium indicus pranii (heat-killed MIP; previously known as Mycobacterium w). MIP was initially developed at the National Institute of Immunology, India as an adjuvant component for use in vaccines and has been evaluated in clinical trials for tuberculosis and various tumors [12,13]. MIP is now licensed and produced as Immuvac/Cadi-05 by Cadila Pharmaceuticals for use as an adjunctive therapy of leprosy [14].…”

mentioning

confidence: 99%